Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108].

Szepeshazi K, Schally AV, Keller G, Block NL, Benten D, Halmos G, Szalontay L, Vidaurre I, Jaszberenyi M, Rick FG.

Oncotarget. 2012 Jul;3(7):686-99.

2.

Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108.

Szepeshazi K, Schally AV, Block NL, Halmos G, Nadji M, Szalontay L, Vidaurre I, Abi-Chaker A, Rick FG.

Oncotarget. 2013 May;4(5):751-60.

3.

AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.

Engel J, Emons G, Pinski J, Schally AV.

Expert Opin Investig Drugs. 2012 Jun;21(6):891-9. doi: 10.1517/13543784.2012.685128. Review.

PMID:
22577891
4.
5.

LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy.

Szepeshazi K, Schally AV, Halmos G.

Int J Oncol. 2007 Jun;30(6):1485-92.

PMID:
17487370
6.
7.

Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.

Seitz S, Buchholz S, Schally AV, Weber F, Klinkhammer-Schalke M, Inwald EC, Perez R, Rick FG, Szalontay L, Hohla F, Segerer S, Kwok CW, Ortmann O, Engel JB.

BMC Cancer. 2014 Nov 19;14:847. doi: 10.1186/1471-2407-14-847.

9.

Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers.

Gründker C, Ernst J, Reutter MD, Ghadimi BM, Emons G.

Oncol Rep. 2011 Sep;26(3):629-35. doi: 10.3892/or.2011.1340. Epub 2011 Jun 7.

PMID:
21667032
10.

Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice.

Koppán M, Nagy A, Schally AV, Plonowski A, Halmos G, Arencibia JM, Groot K.

Prostate. 1999 Feb 1;38(2):151-8.

PMID:
9973101
11.

Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.

Föst C, Duwe F, Hellriegel M, Schweyer S, Emons G, Gründker C.

Oncol Rep. 2011 May;25(5):1481-7. doi: 10.3892/or.2011.1188. Epub 2011 Feb 17.

PMID:
21331448
12.

Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone.

Miyazaki M, Nagy A, Schally AV, Lamharzi N, Halmos G, Szepeshazi K, Groot K, Armatis P.

J Natl Cancer Inst. 1997 Dec 3;89(23):1803-9.

PMID:
9392622
13.

Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone.

Jaszberenyi M, Schally AV, Block NL, Nadji M, Vidaurre I, Szalontay L, Rick FG.

Oncotarget. 2013 Mar;4(3):422-32.

14.

Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.

Engel JB, Keller G, Schally AV, Nagy A, Chism DD, Halmos G.

Fertil Steril. 2005 Apr;83 Suppl 1:1125-33.

PMID:
15831285
15.

Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.

Nagy A, Schally AV, Armatis P, Szepeshazi K, Halmos G, Kovacs M, Zarandi M, Groot K, Miyazaki M, Jungwirth A, Horvath J.

Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7269-73.

18.
19.
20.

Supplemental Content

Support Center